OPTICAL COHERENCE TOMOGRAPHY, FLUORESCEIN ANGIOGRAPHY, AND DIAGNOSIS OF CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION

VINCENT GUALINO, MD,* RAMIN TADAYONI, MD, PhD,* SALOMON YVES COHEN, MD, PhD,† ALI ERGINAY, MD,* FRANCK FAJKUCHEN, MD, PhD,† BELKACEM HAOUCHINE, MD,* VALÉRIE KRIVOSIC, MD,* GABRIEL QUENTEL, MD,† ERIC VICAUT, MD, PhD,‡ ALAIN GAUDRIC, MD, PhD* 

Purpose: To determine the sensitivity and specificity of different retinal imaging combinations for the diagnosis of choroidal neovascularization (CNV) in age-related macular degeneration.

Methods: Patients aged 50 years or older referred for suspicious recent-onset CNV related to age-related macular degeneration were prospectively included for 6 months. Data recorded included color fundus photographs (CFPs), spectral domain optical coherence tomography (SD-OCT), and fluorescein angiography (FA) images. Five retina specialists randomly interpreted SD-OCT combined with CFP, and then FA combined with CFP. The reference diagnosis of CNV was based on the agreement of two readers in the interpretation of the SD-OCT + FA + CFP combination.

Results: One hundred and forty-eight patients (148 eyes) were included. For the diagnosis of CNV, the sensitivity of both SD-OCT + CFP and FA + CFP was of 90.9%. Type 2 CNV was diagnosed in 98% to 100% of cases with SD-OCT + CFP or FA + CFP, whereas Type 1 CNV was diagnosed in 82.9% of cases with SD-OCT + CFP and 81.6% with FA + CFP.

Conclusion: When used as a first diagnostic test, SD-OCT combined with CFP had sensitivity and specificity similar to those of FA combined with CFP, for the diagnosis of CNV in age-related macular degeneration. This shows the increasingly important role of SD-OCT as a first-line test in the diagnosis of CNV.

RETINA 39:1664–1671, 2019

The use of optical coherence tomography (OCT) has progressively emerged as the first-line diagnostic test for detecting exudative age-related macular degeneration (AMD). Although fluorescein angiography (FA) was and may still be considered by some as the gold standard to establish the diagnosis of macular choroidal neovascularization (CNVs),1–3 its concomitant use with OCT has, in fact, become the standard in current practice.4,5 Optical coherence tomography has even progressively emerged as the first-line diagnostic tool for detecting exudative AMD. Thus, combining FA and OCT may be considered the new gold standard for diagnosis of exudative AMD.6,7 Even more, the follow-up of treated eyes, including decisions for re-treatment, is most often only based on OCT findings.8,9 The recent advent of OCT angiography (OCTA) in combination with structural OCT emerges as a possible alternative to FA.7,10 However, OCTA is still an improving technology and is not yet available everywhere. Few studies have compared the diagnostic power of FA and structural OCT to diagnose CNV in AMD and most of them used time domain OCT (TD-OCT).11–13 although spectral domain OCT (SD-OCT), now used in routine, has the advantage to provide a high-density raster of B-scans allowing for mapping more precisely the macular area.14–16 Based on the observation that in current clinical practice, the diagnosis of CNV is often anticipated before obtaining
the results of FA, we aimed to compare the relative performances of SD-OCT combined with color fundus photograph (CFP) and FA combined with CFP for establishing the diagnosis of CNV in patients referred for suspicious exudative AMD. A prospective observational study was then conducted in which several retina specialists read SD-OCT + CFP and FA + CFP images separately without interfering with patient management. Each reader had access to CFP as a surrogate to biomicroscopic fundus examination to be close to the current clinical practice. For each case, the reference diagnosis was made based on the whole data set (SD-OCT + FA + CFP).

**Methods**

This prospective, multicentric, observational study was conducted in two tertiary care retina practices. The Institutional Review Board (IRB)/Ethics Committee of Saint Louis Hospital (Paris) approval was obtained, and digital data management was declared and approved by a French national committee (Commission Nationale de l’Informatique et des Libertés), as required by the French law. The study was also registered in the database of the National Institutes of Health (NIH) on clinicaltrials.gov (identifier no. NCT01080898). All patients signed a consent form for the use of their data.

**Patients**

A total of 148 consecutive patients aged 50 years or older referred for suspicious recent-onset CNV secondary to AMD were included for 6 months (62 patients in Center 1 and 86 in Center 2). Eligibility criteria are summarized in Table 1. Patients were included in the study by the ophthalmologists of the two study centers, referred to as investigators, who did not participate thereafter in the double-masked reading of fundus imaging. Only one eye per patient was included in the study.

**Data Collection**

Only data obtained at the first examination were used, including CFP, SD-OCT, and FA. The study did not interfere with patient management, which was at the investigator’s discretion, regardless of the subsequent interpretation of imaging data by the readers. In practice, imaging data of each patient were duplicated, anonymized, and recorded in a secured computer for further analysis.

**Color fundus photography.** The Topcon TRC 50 DX was used in the two inclusion centers to obtain CFP centered on the macula after pupil dilation.

**Spectral domain optical coherence tomography.** The Cirrus 4000 OCT (Carl Zeiss Meditec, Dublin, CA) was used to acquire a macular cube (128 lines × 512 pixels) and horizontal and vertical 5-line raster scans spaced 75 μm apart centered on the fovea, corresponding to our routine practice.

**Fluorescein angiography.** The Topcon TRC 50 DX digital camera was used in the two inclusion centers. Fifty-degree images centered on the macula were acquired. Four images of the total angiographic sequence were selected for subsequent reading, including early-phase (<30 seconds), mid-phase (<1 minute and <3 minutes), and late-phase (>5 minutes) images.

**Image Interpretation**

Five retina specialists randomly and individually interpreted SD-OCT combined with CFP, and then FA combined with CFP. All data were analyzed in the same center on two dedicated computers. One computer used the Cirrus viewer (Carl Zeiss Meditec),

| Inclusion Criteria | Exclusion Criteria |
|--------------------|--------------------|
| Minimum age: 50 years | Allergy to fluorescein dye |
| Suspicious recent-onset CNV secondary to AMD | Diabetes mellitus |
| First visit to a retina specialist | Previous laser treatment, photodynamic treatment, or intravitreal injection |
| SD-OCT and FA prescribed by the investigator as part of his routine practice | Clear evidence on fundus examination |
| Central retinal vein occlusion | Epiretinal membrane |
| Retinal detachment | Macular hemorrhage >1/3 of the macula |

**Table 1. Eligibility Criteria for Including Patients in the Study**

From the *Ophthalmology Department, AP-HP, Hôpital Lariboisière, Université Paris Diderot, Sorbonne Paris Cité, France; †Centre d’Imagerie et de Laser, Paris, France; and ‡Clinical Research Unit, AP-HP, Hôpital Lariboisière, Université Paris Diderot, Sorbonne Paris Cité, France.

Public Financial Support: Département de la Recherche Clinique et du Développement (DRCD), AP-HP, Paris, France

None of the authors has any conflicting interests to disclose.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Reprint requests: Ramin Tadayoni, MD, PhD, Lariboisière Hospital, 2 rue Ambroise Paré, 75010 Paris, France; e-mail: ramin.tadayoni@aphp.fr
which allowed for interpreting images as in clinical practice with access to all SD-OCT acquired lines. The second computer was used to visualize CFP and FA. Liquid crystal display monitors used had a 1,900 × 1,200-pixel resolution. During each session, each reader interpreted a portion (2/5) of all cases so that each case was interpreted by two different readers. Each reader did not read the same cases on SD-OCT + CFP and FA + CFP to avoid a recall bias. Sessions were spaced by at least 1 month.

The readers were not aware of the ongoing patient management.

During image interpretation, the main objective was to determine whether any type of CNV could be identified or not. When CNV was diagnosed, it was then classified as Type 1 CNV, Type 2 CNV, or “other CNV,” which included retinal angiomatous proliferation and polypoidal choroidal vasculopathy.

Imaging analysis criteria for Sets 1 and 2 are summarized in Tables 2 and 3, respectively. Because the diagnosis was only established based on imaging findings, the readers received no information on the history of symptoms or visual acuity.

Reference Diagnosis

A third session was organized during which each reader randomly and individually interpreted the cases with the combination of SD-OCT, FA, and CFP. Each reader interpreted a portion (2/5) of the total cases so that each case was interpreted by two different readers. The reference diagnosis of CNV was based on the combination of SD-OCT, FA, and CFP when two readers agreed for the diagnosis. In the few cases for which the readers disagreed, a reconciliation session was organized with the five readers to establish the reference diagnosis.

The diagnoses made based on SD-OCT + CFP or FA + CFP were then compared with the reference diagnosis.

Data Analysis

All descriptive analyzes included the mean, SD, median (quartiles), and bilateral 95% confidence intervals (CIs). Each response of a single reader was interpreted as an independent result. The intervariability calculation was based on kappa coefficients.

Statistical calculations were performed using SAS software version 9.2.

Results

Patient median age was 81 years (range: 51–94). One hundred and ten eyes (74.3%, 95% CI [67.3–81.4]) had CNV: 22.7% (95% CI [14.9–30.6]) were Type 2 CNV, 34.6% (95% CI [25.7–43.4]) were Type 1 CNV, and 42.7% (95% CI [33.5–52.0]) were classified as “other CNV.”

A reconciliation session was organized with the 5 readers to establish the reference diagnosis for 12 cases. The sensitivity of SD-OCT combined with CFP to diagnose new-onset CNV was of 90.9% (95% CI [87.1–94.7]) and its specificity was of 88.2% (95% CI [80.9–95.4]). The sensitivity of FA combined with CFP was of 90.9% (95% CI [87.1–94.7]) and its specificity was of 87.7% (95% CI [80.1–95.2]). Type 2 CNV was identified as CNV in 98% and 100% of cases with SD-OCT + CFP and FA + CFP, respectively. Type 1 CNV was identified as CNV in 82.9% and 81.6% of cases with SD-OCT + CFP and FA + CFP, respectively. “Other CNV” was identified as CNV in 93.6% of cases with SD-OCT + CFP or FA + CFP. Results are summarized in Tables 4 and 5. The

| Table 2. Diagnostic Criteria for Set 1: SD-OCT + CFP |
|-----------------------------------------------------|
| For the Diagnosis of Macular CNV in General          | For the Diagnosis of Type 1 CNV | For the Diagnosis of Type 2 CNV |
| Presence on SD-OCT of at least one component from each group | Presence on SD-OCT of at least one component from each group | Presence on SD-OCT of at least one component from each group |
| Irregular elevation of the RPE in the macular area | Irregular elevation of the RPE in the macular area | Hyperreflective fusiform lesion above the RPE |
| Serous pigment epithelial detachment | Ruling out a hyperreflective fusiform lesion above the RPE | Ruling out an irregular elevation of the RPE in the macular area |
| Hyperreflective fusiform lesion above the RPE | Subretinal fluid, even limited | Subretinal fluid, even limited |
| Subretinal fluid, even limited | Macular retinal thickening | Macular retinal thickening |

*Color fundus photograph should not preclude the diagnosis. Cases that could not clearly be identified as Type 1 or Type 2 CNV were classified as “other CNV.” However, if the diagnostic criteria were not fully met, the reader could diagnose CNV based on his own conviction and experience, as he would do in his current practice.
interrater reproducibility of SD-OCT + CFP and FA + CFP for the diagnosis of CNV was kappa = 0.82 and 0.74, respectively. The number of different diagnoses made per reader based on SD-OCT + CFP and FA + CFP compared with the reference diagnosis of the study is shown in Table 6.

| Table 3. Diagnostic Criteria for Set 2: FA + CFP |
|-----------------------------------------------|
| **For the Diagnosis of Macular CNV in General** | **For the Diagnosis of Type 1 CNV** | **For the Diagnosis of Type 2 CNV** |
| At least progressive subretinal dye leakage associated with one of the typical features of CNV subgroups | Vascularized pigment epithelial detachment | Bright area of well-delineated choroidal fluorescence in the early phase of the angiogram |
| Late leakage of undetermined source | |

Color fundus photograph should not preclude the diagnosis. Cases that could not clearly be identified as Type 1 or Type 2 CNV were classified as “other CNV.” However, if the diagnostic criteria were not fully met, the reader could diagnose CNV based on his own conviction and experience, as he would do in his current practice.

Discussion

Optical coherence tomography is commonly used as a reference imaging tool to assess the response of exudative AMD to anti–vascular endothelial growth factor therapy.8,9,17–19 In current practice, when CNV is suspected for the first time, SD-OCT is often the first test performed to guide the diagnosis. However, although FA still remains the reference to establish the diagnosis of CNV,1–3 many studies have shown the increasingly important role of SD-OCT.11,20–22 In this prospective study, we showed that SD-OCT or FA combined with CFP had similar sensitivity (90.9%) and specificity (88.2% for SD-OCT; 87.7% for FA) for the primary diagnosis of CNV due to AMD, in settings close to that of the current practice in patients referred for recent visual impairment due to macular symptoms.

The novelty of our study was to use a combination of SD-OCT, FA, and CFP for the reference diagnosis and not just FA alone, as performed in previous comparable studies, which would have resulted in an unproved 100% accuracy.23 These results thus differ from those of previous studies aiming at comparing the power of OCT and FA to detect a conversion from non–neovascular AMD to neovascular AMD.11,12 The place of FA as a gold standard in CNV diagnosis has also been recently questioned by the results of a retrospective study comparing OCTA combined with structural OCT versus OCTA alone or FA alone, in which FA alone was able to detect Type 1 CNV in only 66.7% of cases, that is, not more than what was detected with OCTA alone.10 In the past, the use of TD-OCT has shown sensitivity and specificity less than those of FA.11,12,24

Our study, which was designed and performed before the availability of OCTA, anticipated the obsolescence of FA alone as a gold standard and we therefore used the combination of multimodal tests, SD-OCT, FA, and CFP for the reference diagnosis.

Other studies have shown a good sensitivity with SD-OCT for detecting CNV. In a study only assessing 21 eyes, Park et al25 have found a sensitivity of 100%. Wilde et al23 have reported sensitivity and specificity of SD-OCT for detecting CNV of 100% and 80.8%, respectively. However, they concluded that SD-OCT cannot replace FA in the diagnosis of neovascular AMD in current clinical practice because of a lower specificity and higher false-positive rates compared with FA. Other studies have found a very high sensitivity of SD-OCT, close to 100%, for detecting CNV activity.23,25,26 But all these studies used FA as the gold standard and when SD-OCT showed some CNV activity, whereas FA did not, it was

| Table 4. Sensitivity for the Diagnosis of CNV: Overall Sensitivity and Sensitivity for the Different CNV Types |
|---------------------------------------------------------------|
| Tests                                         | Overall Sensitivity (%) | Sensitivity for Type 1 CNV (%) | Sensitivity for Type 2 CNV (%) | Sensitivity for Other CNV (%) |
|-----------------------------------------------|-------------------------|-------------------------------|-------------------------------|-----------------------------|
| FA + CFP                                       | 90.9                    | 100                           | 81.6                          | 93.6                         |
| SD-OCT + CFP                                   | 90.9                    | 98                            | 82.9                          | 93.6                         |
considered as a false-positive and decreased SD-OCT specificity. In fact, it is likely that SD-OCT in some cases is more sensitive than the presumed gold standard, FA, and that minimal SD-OCT signs may represent very early structural changes that occur before a leak detectable with FA in some eyes.27,28

All study readers were retina specialists experienced with all imaging techniques used. None of the readers seemed to have obviously overdiagnosed or underdiagnosed based on a specific imaging modality with an obvious difference compared with the reference diagnosis.

However, it should be noted that the interobserver agreement for SD-OCT + CFP was greater than that for FA + CFP, which corresponds to a greater degree of reproducibility in the interpretation of SD-OCT + CFP examination. Similar findings have been reported by Inoue et al10 by comparing OCTA alone and OCTA combined with structural OCT and FA.

Overall, SD-OCT + CFP or FA + CFP had the same power and limitation for the diagnosis of CNV because both techniques had an excellent sensitivity of 90.9%. In case of Type 2 CNV, the performance of SD-OCT + CFP and FA + CFP was very high (98 and 100%, respectively) for the suspected diagnosis of CNV, whereas both techniques were less powerful in case of Type 1 CNV (sensitivity of 82.9 and 81.6%, respectively).

In less than 10% of cases, in our study, SD-OCT + CFP (9.8%) or FA + CFP (9.9%) resulted in different diagnoses compared with the reference diagnosis (SD-OCT + FA + CFP) because of various causes.

Most often for the SD-OCT + CFP set, confluent soft drusen were present and SD-OCT + CFP did not show CNV, despite an irregular elevation of the retinal pigment epithelium (RPE) on SD-OCT because of the absence of subretinal fluid or retinal thickening. However, after FA + CFP reading, the readers diagnosed CNV because they observed a late fuzzy hyperfluorescence with some pin points on FA. In other cases, a small shallow extrafoveal subretinal fluid area was missed on SD-OCT, whereas FA easily showed a suggestive aspect of Type 1 CNV (Figure 1). By contrast, in other cases, FA + CFP did not allow for detecting CNV in patients with multiple drusen and atrophy, whereas SD-OCT + CFP revealed a small area of subretinal fluid (Figure 2). In one case, an epiretinal membrane was clearly visible on SD-OCT + CFP, whereas the reader of FA + CFP identified CNV. Adding two different imaging sources changes the way to detect suspected CNV, especially Type 1 CNV. In particular, in recent-onset cases with incomplete features or cases with atypical presentation, it seemed that combining SD-OCT, FA, and CFP findings was beneficial.

This study has some limitations. Each reader had access to CFP as a surrogate to biomicroscopic fundus examination to be close to the current clinical practice. However, it was not stereophotography, which would have allowed clinicians to view retinal thickness and macular edema. The diagnosis was simply based on a consensus opinion because no follow-up data were included in this study. The reference was purely qualitative because we did not try to quantify any CNV feature. We did not follow the procedures of a reading center,29 but rather remained as close as possible to the current practice: the reading was made by retina specialists involved in the management of exudative AMD and relied on their clinical expertise. The study was performed using the Cirrus 4000 spectral domain OCT. Results could have been different with a device including eye

| Table 5. Specificity for the Diagnosis of CNV and Interrater Reproducibility |
|-----------------------------|-----------------------------|-----------------------------|
| Tests | Specificity (%) | Interrater Reproducibility |
| FA + CFP | 87.7 | Kappa = 0.74 |
| SD-OCT + CFP | 88.2 | Kappa = 0.82 |

| Table 6. Number of Different Diagnoses Made Per Reader Based on SD-OCT + CFP and FA + CFP Compared With the Reference Diagnosis of the Study (SD-OCT + FA + CFP) |
|-----------------------------|-----------------------------|-----------------------------|
| No. of Different Diagnoses Made Using OCT + CFP Reading Compared With the Reference Diagnoses of the Study (P = 0.43) | No. of Different Diagnoses Made Using FA + CFP Reading Compared With the Reference Diagnoses of the Study (P = 0.7) | Total No. of Different Diagnoses During Reading Sessions Compared With the Reference Diagnoses of the Study (P = 0.39) |
| Reader 1 | 6 | 4 | 10 |
| Reader 2 | 3 | 4 | 7 |
| Reader 3 | 4 | 8 | 12 |
| Reader 4 | 9 | 7 | 16 |
| Reader 5 | 6 | 6 | 12 |
tracking and averaging. However, the advantage of this device was to simply provide a high-density mapping with acquisition of a dense macular cube (128 lines × 512 pixels) in 2.4 seconds. In this study, we did not use indocyanine green angiography because this test is not routinely used in current practice. Indocyanine green angiography could help making a diagnosis, especially in some cases with Type 1 CNV or polypoidal choroidal vasculopathy. The investigators could ask to perform indocyanine green angiography and it was performed for some patients, but this examination was not used to make the reference diagnosis. As indocyanine green angiography is not routinely used as a first diagnostic tool, we preferred to mimic the situation upstream of its prescription.

Our study was conducted before OCTA was available. This new technique will certainly change completely the paradigm of CNV detection in association with structural OCT and we have previously shown its value.7 Our results may thus also be useful for designing prospective studies assessing the value of SD-OCT combined with OCTA capacities for the diagnosis of CNV. For example, the benefit of OCTA in terms of sensitivity for the diagnosis of CNV should be more easily confirmed in Type 1 CNV than in Type 2 CNV.
where structural OCT + CFP has already a nearly 100% sensitivity. This work could also have an interest in the development of telemedicine. The combination of SD-OCT and CFP has the advantage of not requiring the presence of a physician and could be a valid telemedicine or computer artificial intelligence screening method for AMD where the access to retina specialists is limited.

In conclusion, our results showed no statistical difference between SD-OCT + CFP and FA + CFP in terms of sensitivity and specificity to detect the presence of recent-onset CNV secondary to AMD when the reference diagnosis is based on SD-OCT combined with FA and CFP. The sensitivity of SD-OCT + CFP, such as FA + CFP, in Type 2 CNV is very high. If Type 1 CNV is suspected, combining both imaging techniques could be needed until determining whether OCTA is sensitive enough.

**Key words:** age-related macular degeneration, color fundus photography, choroidal neovascularization, optical coherence tomography, fluorescein angiography, sensitivity, specificity.

**References**

1. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009;116: S15–S23.
2. Harding SP. Neovascular age-related macular degeneration: decision making and optimal management. Eye (Lond) 2010; 24:497–505.
3. Bermig J, Tylla H, Jochmann C, et al. Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002;240:169–175.
4. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010;30:1333–1349.
5. Jung JJ, Chen CY, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol 2014;158:769–779 e762.
6. Rosenfeld PJ. Optical coherence tomography and the development of antiangiogenic therapies in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2016;57: OCT14–OCT26.
7. Cohen SY, Mrejen S. Imaging of exudative age-related macular degeneration: toward a shift in the diagnostic paradigm? Retina 2017;37:1625–1629.
8. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143:566–583.
9. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONT0 Study. Am J Ophthalmol 2009;148:43–58 e41.
10. Inoue M, Jung JJ, Balaratnasingam C, et al. A comparison between optical coherence tomography angiography and fluorescein angiography for the imaging of type 1 neovascularization. Invest Ophthalmol Vis Sci 2016;57:OCT314–OCT323.
11. Padnick-Silver L, Weinberg AB, Lafranco FP, Macsai MS. Pilot study for the detection of early exudative age-related macular degeneration with optical coherence tomography. Retina 2012;32:1045–1056.
12. Do DV, Gower EW, Cassard SD, et al. Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology 2012;119:771–778.
13. Do DV. Detection of new-onset choroidal neovascularization. Curr Opin Ophthalmol 2013;24:244–247.
14. Cukras C, Wang YD, Meyerle CB, et al. Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices. Eye (Lond) 2010;24:775–783.
15. Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology 2010;117:1376–1380.
16. Major JC Jr, Wykoff CC, Mariani AF, et al. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Retina 2014;34:48–54.
17. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193–201.
18. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EUR-ETINA). Br J Ophthalmol 2014;98:1144–1167.
19. Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunovic H. A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond) 2017;31:26–44.
20. Sandhu SS, Talks SJ. Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes. Br J Ophthalmol 2005;89:967–970.
21. Keane PA, Patel PJ, Liakopoulou S, et al. Evaluation of age-related macular degeneration with optical coherence tomography. Surv Ophthalmol 2012;57:389–414.
22. Giani A, Luiselli C, Esmaili DD, et al. Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization. Invest Ophthalmol Vis Sci 2011;52:5579–5586.
23. Wilde C, Patel M, Lakshmanan A, et al. The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography. Eye (Lond) 2015;29:602–609; quiz 610.
24. Castillo MM, Mowatt G, Elders A, et al. Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review. Ophthalmology 2015;122:399–406.
25. Park SS, Truong SN, Zawadzki RJ, et al. High-resolution Fourier-domain optical coherence tomography of choroidal neovascular membranes associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51:4200–4206.
26. Talks J, Koshz Z, Chatzinikolas K. Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration. Br J Ophthalmol 2007;91:600–601.
27. Amissah-Arthur KN, Panneerselvam S, Narendran N, Yang YC. Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration. Eye (Lond) 2012;26:394–399.
28. Carnevali A, Cicinelli MV, Capuano V, et al. Optical coherence tomography angiography: a useful tool for diagnosis of treatment-naive quiescent choroidal neovascularization. Am J Ophthalmol 2016;169:189–198.
29. DeCroos FC, Toth CA, Stinnett SS, et al. Optical coherence tomography grading reproducibility during the comparison of age-related macular degeneration treatments trials. Ophthalmology 2012;119:2549–2557.